09.16.25 -- Buckle Up. It's A Strategic Drive To Successful Sourcing

Explore 20+ new CDMO presenters in quick 20-minute sessions during Outsourced Pharma’s October Partner Week. Sessions include Analytical Services, ADC, Large and Small Molecules, Cell and Gene Therapy, and Fill/Finish. Each session offers a quick, informative look at capabilities to help you find the best-fit partner. Registration, on-demand access, and interactive Q&A are all free.

Review the importance of alternative approaches to viral vector production and the benefits of intensified adherent cell culture for improving efficiency, reducing costs, and accelerating development.

Cell and gene therapies require adaptive and advanced assays for characterization and safety assessments, and assays historically used for biologics must diversify to accommodate them.

To overcome manufacturing bottlenecks and reduce the high cost of gene therapies, our ATLAS platform has identified novel factors that boost rAAV9 production over 30-fold.

Logic gating applies Boolean logic principles to CAR T cell design to improve precision and minimize collateral damage.

Explore how platform processes advance gene therapies, the impact of strong partnerships on patient access, and the future shaped by these collaborations.

This HEK293-derived, animal component-free suspension cell line forms the foundation of a scalable, robust platform process that accelerates AAV manufacturing.

From enabling earlier insights through donor characterization to reducing manufacturing variability through cell separation technologies, explore case studies and actionable approaches to scale smarter.

Access a thorough investigation that delves into the critical aspects of expediting curative therapies, with a focus on the strategic role that CDMOs can play in this transformative journey.

Observe how to transform biopharma learning with a human-centered, AI-enhanced ecosystem that personalizes development, fosters engagement, and aligns training with real-world impact.

Specialized cell collection services depend on access to a large, diverse donor pool as well as robust donor screening and efficient collection practices.

Low AAV productivity and lack of platform processes are key challenges driving AAV production cost up. Explore a robust and scalable suspension manufacturing platform for AAV production.

A comprehensive Quality Risk Analysis and Control Strategy is built on five key pillars, each playing a vital role in ensuring that every final product meets the highest safety and efficacy standards.

Discover a platform that offers clients a personalized, responsive, and expert-driven approach to process development and manufacturing from early clinical to pivotal supply and commercial launch.

Designed as a dedicated, short-range logistics service for the life sciences, Cryoshuttle reinforces chain of custody, ensures near real-time visibility, and preserves product integrity from start to finish.

The Curator adherent platform has been used to manufacture more than 450 Phase 1 and 2 clinical batches, spanning over 17 years and covering a variety of serotypes and indications.

Experience expert vector design and speed. Find rapid access to high quality, optimized-by-design Lentiviral vectors for clinical development and commercialization for a fraction of the expected cost.